ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report)’s stock price hit a new 52-week low during trading on Friday . The stock traded as low as $4.73 and last traded at $4.76, with a volume of 2570805 shares changing hands. The stock had previously closed at $5.06.
Key Stories Impacting ARS Pharmaceuticals
Here are the key news stories impacting ARS Pharmaceuticals this week:
- Positive Sentiment: Brokerage analysts maintain a consensus rating of “Moderate Buy,” suggesting some Wall Street analysts continue to see potential upside despite the recent weakness. ARS Pharmaceuticals Given Consensus Rating of Moderate Buy
- Neutral Sentiment: A reported short-interest update showed zero shares sold short both before and after the measurement period, with a zero-day days-to-cover ratio. The figures appear inconsistent or incomplete, so they provide little dependable insight into current trading sentiment.
- Negative Sentiment: Several investor-rights firms, including Rosen, Bronstein Gewirtz & Grossman, Bragar Eagel & Squire, SBS Law, Faruqi & Faruqi and Kaplan Fox, announced or promoted the pending class action against ARS Pharmaceuticals and certain officers. The case covers investors who purchased SPRY securities from March 9 through June 24, 2026, and alleges violations of federal securities laws. SPRY Investors Have Opportunity to Lead Securities Fraud Lawsuit
- Negative Sentiment: The allegations reportedly focus on whether ARS and executives—including Chief Commercial Officer Eric Karas—misled investors about the timing of expanded CVS Caremark coverage for neffy, after SPRY shares fell 23.9% in one session. Although the allegations have not been proven, the litigation could create legal costs, prolong uncertainty and weigh on investor confidence. SueWallSt ARS Pharmaceuticals Class Action Reminder
Analysts Set New Price Targets
A number of brokerages recently issued reports on SPRY. Wall Street Zen raised shares of ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Cantor Fitzgerald upped their target price on ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 28th. Weiss Ratings downgraded ARS Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, August 17th. Finally, Leerink Partners set a $15.00 price target on ARS Pharmaceuticals in a research note on Tuesday. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, ARS Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $26.40.
ARS Pharmaceuticals Price Performance
The business’s fifty day moving average price is $6.24 and its 200 day moving average price is $7.76. The company has a quick ratio of 3.28, a current ratio of 3.48 and a debt-to-equity ratio of 13.72.
ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.15). The company had revenue of $33.66 million for the quarter, compared to the consensus estimate of $31.32 million. ARS Pharmaceuticals had a negative net margin of 184.24% and a negative return on equity of 256.67%. As a group, analysts anticipate that ARS Pharmaceuticals, Inc. will post -1.9 EPS for the current year.
Institutional Trading of ARS Pharmaceuticals
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bessemer Group Inc. increased its holdings in shares of ARS Pharmaceuticals by 3,102.1% during the first quarter. Bessemer Group Inc. now owns 7,525 shares of the company’s stock worth $61,000 after buying an additional 7,290 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in shares of ARS Pharmaceuticals during the 4th quarter valued at $65,000. Russell Investments Group Ltd. boosted its holdings in shares of ARS Pharmaceuticals by 197.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock valued at $67,000 after acquiring an additional 4,427 shares in the last quarter. Alpine Woods Capital Investors LLC bought a new stake in ARS Pharmaceuticals during the 1st quarter worth $80,000. Finally, Syon Capital LLC acquired a new position in ARS Pharmaceuticals in the 2nd quarter worth about $80,000. Institutional investors own 68.16% of the company’s stock.
ARS Pharmaceuticals Company Profile
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.
Featured Stories
- Five stocks we like better than ARS Pharmaceuticals
- Block Makes a Federal Trust Bank Move That Could Reshape Its Fintech Model
- Kroger’s Textbook Entry for Buy-and-Hold Investors
- AST SpaceMobile Looks to Extend Its 30-Day FCC Satellite Testing Window
- Amgen Drops 10% on a Trial It Didn’t Even Run
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
